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RESEARCH ARTICLES
AAV-Mediated TAZ Gene Replacement Restores Mitochondrial
and Cardioskeletal Function in Barth Syndrome
Silveli Suzuki-Hatano,1 Madhurima Saha,1 Skylar A. Rizzo,1 Rachael L. Witko,1
Bennett J. Gosiker,1 Manashwi Ramanathan,1 Meghan S. Soustek,1,2 Michael D. Jones,1
Peter B. Kang,1,2 Barry J. Byrne,1,2 W. Todd Cade,3 and Christina A. Pacak1,2,*
Departments of 1Pediatrics and 2Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida;
3Program in Physical Therapy, Washington University School of Medicine, St. Louis, Missouri.
Barth syndrome (BTHS) is a rare mitochondrial disease that affects heart and skeletal muscle and has no
curative treatment. It is caused by recessive mutations in the X-linked gene TAZ, which encodes tafazzin.
To develop a clinically relevant gene therapy to restore tafazzin function and treat BTHS, three different
adeno-associated virus serotype 9 vectors were tested and compared to identify the optimal promoter—
cytomegalovirus (CMV), desmin (Des), or a native tafazzin promoter (Taz)—for TAZ expression following
intravenous administration of 1 · 1013 vector genomes/kilogram to a mouse model of BTHS as either neo-
nates (1–2 days of age) or adults (3 months of age). At 5 months of age, evaluations of biodistribution and
TAZ expression levels, mouse activity assessments, fatigue in response to exercise, muscle strength, cardiac
function, mitochondrial structure, oxygen consumption, and electron transport chain complex activity as-
says were performed to measure the extent of improvement in treated mice. Each promoter was scored for
significant improvement over untreated control mice and significant improvement compared with the other
two promoters for every measurement and within each age of administration. All three of the promoters
resulted in significant improvements in a majority of the assessments compared with untreated BTHS
controls. When scored for overall effectiveness as a gene therapy, the Des promoter was found to provide
improvement in the most assessments, followed by the CMV promoter, and finally Taz regardless of in-
jection age. This study provides substantial support for translation of an adeno-associated virus serotype
9–mediated TAZ gene replacement strategy using a Des promoter for human BTHS patients in the clinic.
Keywords: cardiac gene therapy, mitochondrial disease, AAV9, tafazzin, Barth syndrome, promoter
comparison
INTRODUCTION
BARTH SYNDROME (BTHS) is a rare, frequently fatal,
mitochondrial disease caused by recessive loss-of-
function mutations in the X-linked gene TAZ,
which encodes tafazzin. Tafazzin is a nuclear-
encoded acyltransferase that is trafficked to the
inner mitochondrial membrane. Under normal
conditions, cardiolipin (CL) becomes degraded to
monolysocardiolipin (MLCL) and is then converted
back to mature CL by tafazzin. However, in BTHS
this cycle is impaired and the accumulation of MLCL
eventually leads to increased MLCL/CL ratios.1–5
The unique composition of mature CL is responsible
for maintenance of mitochondrial membrane fluidity,
osmotic stability, and proper curvature of the cristae,
which serves as a crucial binding site for electron
transport chain (ETC) proteins and stabilization of
the ETC supercomplexes.6–9 In BTHS mitochondria,
the increased MLCL/CL ratios result in abnormal
cristae formation and inefficient ETC-mediated ATP
production.
The timing and clinical presentation of BTHS
is variable; however, typical symptoms include
cardioskeletal myopathy, neutropenia, and 3-
methylglutaconic aciduria, with cardiomyopathy
being the primary cause of death.10–13 Impaired
cardiac and skeletal muscle bioenergetics, de-
creased cardiac reserve, and diminished skeletal
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muscle O2 utilization all contribute to an overall
phenotype of cardioskeletal myopathy.11,13 Cur-
rent clinical BTHS standard of care includes ad-
ministration of medications such as diuretics and
ACE inhibitors; no other treatment options are
available for these patients.10 Recessive single-
gene defect disorders such as BTHS are optimal
targets for gene replacement strategies. The po-
tential for various gene delivery systems to correct
TAZ deficiency has been demonstrated in Sacchar-
omyces cerevisiae, Drosophila melanogaster, Danio
rerio, and in vitro iPSC BTHS models.5,14–16 In all of
these, replacement of TAZ demonstrated improve-
ment in the BTHS disease phenotypes (motor
weakness, mitochondrial respiration, in vitro cardi-
omyocyte contractile function). In sum, these studies
strongly support development of a clinically relevant
gene therapy approach to treat BTHS.
Recombinant adeno-associated virus (rAAV) vec-
tors are ideally suited for gene therapy approaches
because the rAAV used for gene delivery is a non-
pathogenic virus (with all viral genes removed) that
elicits a minimal immune response and rAAV per-
sists for long periods of time as an episome within the
nucleus of cells providing stable gene transfer with-
out disruption of genes by insertional mutagenesis.17
Employing several layers of vector optimization re-
duces the minimal effective dose and ultimately
lowers both the cost of the therapeutic as well as the
risk of side effects for patients. Identification of an
ideal tissue restrictive promoter for use in a gene
delivery system is one layer of optimization that we
test in this study; another is the use of specific sero-
types. Many laboratories performing independent
AAV serotype comparison studies have concluded
that AAV serotype 9 (AAV9) is the most naturally
cardiotropic serotype available to date.18–22 In addi-
tion to a high affinity for the heart, intravenous ad-
ministration of AAV9 has also been shown to provide
exceptional transduction of skeletal muscle.18,19,22,23
Here we describe a study designed to test and
compare three different AAV2/9-TAZ vectors that
each contain a different promoter to drive TAZ
expression. One is a ubiquitous cytomegalovirus
(CMV) promoter, another is a desmin (Des) pro-
moter that is expected to provide high expression in
heart and skeletal muscle and lower expression in
nonmuscle, nonheart tissues such as liver, and the
final promoter is the native Taz promoter, which is
expected to provide more natural TAZ expression
levels across all tissues. Our goal was to identify
which promoter was the most effective at improv-
ing BTHS pathophysiology at each injection age.
Assessments included evaluations of TAZ expres-
sion levels and biodistribution, mouse activity as-
sessments, fatigue in response to exercise, muscle
strength, cardiac function, mitochondrial struc-
ture, oxygen consumption, and electron transport
chain complex activity assays. Our data demon-
strate successful correction of BTHS through sig-
nificant organelle (mitochondria), organ (heart and
skeletal muscle), and whole body functional im-
provements with all three promoters with Des be-
ing the most effective promoter regardless of
injection age. In sum, we present preclinical data
that provide strong support for further translation
of BTHS gene therapy into the clinical realm.
MATERIALS AND METHODS
Tafazzin short hairpin RNA knockdown mice
The University of Florida Institutional Animal
Care and Use Committee approved all animal
studies. Wild type (WT) C57BL/6J female mice
were mated to transgenic males (ROSA26
H1/TetO-shRNA:taz) CB57BL/129S6 (previously char-
acterized Tafazzin shRNA knockdown [TazKD]
mouse model) for 5 days.24–28 Females were then
separated from males and placed on a doxycycline
(dox) diet containing 200 mg of dox/kg chow
(TD98186; Envigo). Transgenic pups were identi-
fied by PCR genotyping of tail genomic DNA and
maintained on the dox diet throughout their lives
(TazKD). Nontransgenic WT littermates were also
fed the dox diet and used as wild type controls in all
experiments.
AAV vector design and administration
The promoter-TAZ sequences were cloned into
a previously described double-stranded (ds) AAV
plasmid sequence kindly provided by Dr. Xiao29.
Two of the plasmids contain the previously de-
scribed desmin (Des) and CMV promoters and the
other is Taz, a native tafazzin promoter, which
contains the immediate 1071 bp sequence of the
upstream 5¢ untranslated region of TAZ. Each
promoter drives expression of the full-length hu-
man TAZ transgene complementary DNA (cDNA)
(CCDS14748.1) tagged with a myc sequence and
contains a poly-A tail. Each dsAAV plasmid was
packaged into recombinant AAV9 capsids that
were generated and titered at the University of
Florida Vector Core facility in parallel using a
TAZ probe and a well-established dot-bot meth-
od.30 dsAAV9-CMV-TAZ, dsAAV9-Des-TAZ, and
dsAAV9-Taz-TAZ were each administered to
TazKD mice at a dose of 1 · 1013 vg/kg. Adult in-
jections were administered through the jugular
vein (at 3 months of age) and neonatal injections
were administered through the superficial tem-
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poral vein (at 1–2 days of age) as previously de-
scribed.19 All in vivo assessments were performed
at 5 months of age. Upon the completion in vivo
experiments, mice were euthanized the same
week and necropsies performed to enable force
mechanics studies or mitochondrial oxygen con-
sumption assays on freshly isolated tissues.
Other tissues were collected and stored at -80C
until needed for other assays.
Vector genome assessments
A standard curve was generated by spiking in
known quantities of TAZ plasmid into a back-
ground of negative control genomic DNA from
wild type mice and performing quantitative PCR
using a TAZ primer-probe. Genomic DNA was
extracted from frozen tissues (n = 3 per tissue, per
treatment cohort) using the Quick-DNA micro-
prep kit (Zymo) and evaluated using the same
TAZ primer-probe (45 ng of DNA per reaction).
Vector genomes per diploid cell were calculated as
previously described.19,31
RT-PCR gene expression analyses
Total RNA was isolated from frozen tissues us-
ing the RNA Extraction kit (Zymo). cDNA was
synthesized using the High Capacity RNA-to-
cDNA kit (Applied Biosystems) and quantitative
real-time (RT)-PCR was performed using TaqMan
Master Mix (Thermo Scientific) and specific prim-
ers (Supplementary Table S1) (Thermo Scientific)
on a StepOnePlus Real-Time PCR System (Applied
Biosystems). Relative expression levels were cal-
culated using the DDCt method to determine fold
change as compared to control levels.
Protein quantification
and Western blot analyses
Tissues were homogenized in RIPA lysis buffer
containing protease and phosphatase inhibitors.
Protein concentrations were determined using
the DC Protein Assay kit (BioRad). Samples were
resolved on 5–10% bis-tris polyacrylamide dena-
turing gels and transferred to nitrocellulose
membranes using standard techniques. Mem-
branes were incubated with primary antibodies
(Supplementary Table S2) overnight at 4C.
Membranes were washed with 1 · Tris-buffered
saline with Tween, incubated with secondary
antibodies conjugated to horseradish peroxidase
(1:1000) for 1 h, and washed again. Bands were
detected using the Amersham ECL Prime Wes-
tern Blotting Detection Reagent (GE Healthcare
Life Science).
Myc pulldown assay
Tissues were homogenized in RIPA lysis buffer
containing protease and phosphatase inhibitors.
Protein lysate concentrations were determined us-
ing the DC Protein Assay kit (BioRad). One hundred
micrograms of total protein were incubated for 16 h
at 4C with 100 lL of Pierce Anti-c-Myc Agarose
(Thermo Scientific), washed 3· with Tris-buffered
saline with 0.05% Tween-20 detergent and eluted
from beads by boiling in Laemmli sample buffer.
Immunofluorescence microscopy
Freshly excised tissue samples were fixed in 10%
neutral buffered formalin overnight at 4C. Fol-
lowing fixation, tissues were embedded in paraffin
and sectioned using standard methods. Slides were
dried overnight at 37C, dewaxed, rehydrated, and
subjected to antigen retrieval using trypsin-EDTA.
Slides were blocked in phosphate-buffered saline
(PBS) +5% bovine serum albumin (BSA) for 1 h at
room temperature then incubated in 1 antibodies
(Supplementary Table S2) diluted in PBS +5% BSA
overnight at 4C. Following washes, slides were
incubated in 2 antibodies diluted (1:200) + 1 lg/mL
4¢,6-diamidino-2-phenylindole (Sigma Aldrich) in
PBS +5% BSA for 1 h at room temperature. Slides
were rinsed in 1 · PBS, mounted in VectaMount
and stored at 4C. Immunofluorescence (IF) images
were acquired within 24 h of immunolabeling.
Activity and fatigue analyses
Rearing, distance, resting times, and mean ve-
locity activities were evaluated in 5 month old mice
using the ActiTrack v2.7 system (Panlab software)
as previously described with slight modifications.32–34
Briefly, mice were placed in the detection cham-
ber to assess total distance and vertical activity for
6 minutes prior to exercise. Next, the mice were
mildly exercised on a treadmill (5 min at 3 m/min
followed by an increase to 10 m/min for 10 min).
Post-treadmill activity was then measured using
the same method described for pre-treadmill ac-
tivity. Zone map tracings were created using the
Actitrack mapping software where the x and y
planes represent the two dimensions of the activity
chamber, and the bold lines represent every time
the mouse breaks the z plane, registering as ver-
tical activity within each 6 min time interval (pre-
and postexercise). Each mouse was tested twice by
blinded observation.
Echocardiography analyses
Five month old mice were anesthetized using a
mixture of 1.5% isoflurane and O2. Acquisitions were
obtained using the LOGIQ system and software
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(GE Health Care). Long axis echocardiography
(echo) measurements at the minor chord dimension
were acquired in a standard long axis view. Short
axis measurements were acquired on all mice at 5
months of age just below the midpapillary muscle. At
least 10 consecutive beats of the left ventricular in-
terior dimension (LVID) were recorded for both end
diastole and end systole in each view. These mea-
surements were averaged to calculate LVIDd (end
diastolic) and overall fractional shortening for func-
tional comparisons. The left ventricular posterior
wall thickness was measured in end diastole for at
least 10 consecutive beats and averaged.
Force mechanics
Soleus muscles were isolated from mice with the
tendons attached and suspended vertically in a
water-jacketed bath containing Krebs–Henseleit
solution equilibrated with a 95% O2/5% CO2 gas
mixture and maintained at 37C. Solei were stimu-
lated using two vertical platinum electrodes. Con-
tractile properties were measured isometrically
following determination of optimum length. Peak
isometric tetanic force was measured at 160 Hz using
a 500 ms train with a 2 min recovery period. Muscle
fatigue was determined by measuring isometric
contractile force stimulated by 250 ms, 30 Hz trains
occurring every 4 s over a 5 min period. A force fre-
quency relationship was determined by stimulating
muscles to contract using a 500 ms train with a 2 min
recovery period at the following frequencies: 15 Hz,
30 Hz, 60 Hz, 100 Hz, 160 Hz, and 200 Hz. Equip-
ment included: Grass AC/DC Strain Gage Amplifier
(model P122), Aurora Scientific Inc. Signal Interface,
Grass S48 Stimulator, Grass Force Displacement
Transducer (model FT03), ASI 610A Dynamic Mus-
cle Control v5.420 software for data collection, and
ASI 611A Dynamic Muscle Analysis v5.110 software.
Electron micrograph processing and analyses
Freshly excised 3 mm · 3 mm left ventricular
wall heart tissue samples were placed in Kar-
novsky’s fixative (2% paraformaldehyde/2.5% glu-
taraldehyde in 0.1 M sodium cacodylate buffer) and
maintained at 4C until processing. Tissue em-
bedding, sectioning, and imaging were performed
by the Emory University Robert P. Apkarian In-
tegrated Electron Microscopy Core. All measure-
ment analyses were performed by laboratory
personnel blinded to sample identities using Im-
ageJ software (National Intitutes of Health).
Oxytherm analyses
Mitochondrial isolations were performed on
fresh heart tissue as previously described.35 Oxy-
gen consumption measurements were acquired by
diluting samples (n 5 per group) in 0.5 mL of res-
piration buffer (Mir05: 0.5 mM EGTA, 3 mM
MgCl2, 60 mM lactobionic acid, 20 mM taurine,
10 mM KH2PO4, 20 mM HEPES, 110 mM sucrose,
1 g/L BSA) in the chamber of an Oxytherm elec-
trode unit (Hansatech, Norfolk, UK) at 37C with
constant stirring speed (60 rpm). The probe elec-
trodes were calibrated with sodium dithionite (0%
oxygen) and respiration buffer (100% oxygen) as
recommended by the manufacturer. The measure-
ments were acquired following additions of: 100 lL
of isolated mitochondria, 10lL substrate (0.25 M
glutamate/0.125 M malate), 7.5 lL 10 mM adeno-
sine 5¢-diphosphate sodium salt (ADP) (state 3),
0.5lL of oligomycin (5mg/mL) (state 4o), and 1 lL of
100lM carbonyl cyanide 4-(trifluoromethoxy) phe-
nylhydrazone (FCCP) (state 4u).
ETC complex activity assays
All complex activity assays (CI, complex 1; CII,
complex 2; and CIII, complex 3) were performed on
homogenates of isolated cardiac mitochondria from
mice at 5 months of age in triplicate (n = 5 per
group) using a published protocol.36 Briefly, CI
activity was determined by oxidation of NADH to
NAD at 340 nm using a SpectraMax i3x. Ten mi-
croliters of isolated mitochondrial homogenate was
diluted into 90 lL of 50 mM phosphate buffer (pH
7.5), 100 lM NADH, 60 lM ubiquinone, 3 mg/mL
fatty acid-free BSA, 300 lM potassium cyanide
(KCN), and 10 lM rotenone (in parallel). CI activity
was described as % inhibition following addition of
rotenone. CII activity was determined by reduction
of DCPIP (2,6-diclorophenolindophenol sodium
salt hydrate) at 600 nm. Ten microliters of isolated
mitochondrial homogenate was diluted into 90 lL
of 25 mM phosphate buffer (pH 7.5), 1 mg/mL fatty
acid-free BSA, 300 lM KCN, 20 mM succinate,
50 lM decylubiquinone, 80 lM DCPIP, and 10 mM
malonate (in parallel). CII activity was described
as % inhibition following addition of malonate. CIII
activity was measured as the conversion of oxidized
cytochrome c to a reduced form at 550 nm. 10 lL of
mitochondrial homogenate was diluted into 90 lL
of 25 mM phosphate buffer (pH 7.5), 75 lM oxidized
cytochrome c, 500 lM of KCN, 100 lM EDTA (pH
7.5), 0.025% (vol/vol) Tween-20, 100 lM of decylu-
biquinol and 10 lg/mL antimycin A (in parallel).
CIII activity was described as % inhibition follow-
ing addition antimycin A.
Statistical analyses
Data were analyzed for significance using SPSS
Software. Values are reported as mean – standard
142 SUZUKI-HATANO ET AL.
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error. Significant differences were determined by
nonparametric Kruskal Wallis and Dunn post-hoc
tests. Differences between promoter groups from
the same age of injection are indicated by an as-
terisk (*) and lines above bars. Significant im-
provement between each cohort and untreated
TazKD controls are indicated by an asterisk (*) at
the bottom of bars (*p £ 0.05, **p £ 0.01, ***p £ 0.001
were considered statistically significant).
RESULTS
CMV, Des, and Taz promoters provide
differential TAZ expression profiles in vivo
Recombinant AAV includes two flanking palin-
dromic inverted terminal repeats that are essential
for virus replication and for packaging into cap-
sids37. In order to develop the optimal gene delivery
vector for BTHS, we created three different TAZ
expression cassettes flanked by inverted terminal
repeats designed to efficiently generate double-
stranded (dsAAV) vectors (Fig. 1A).29 One contains
a CMV promoter to provide robust, long-term TAZ
expression in a wide variety of tissues. Another
contains a previously described desmin promoter
(Des) that has been shown to drive efficient trans-
gene expression in striated (heart and skeletal)
muscle.23,38 We also evaluated the ability of the
5¢ untranslated region of TAZ to serve as an effi-
cient promoter (Taz). This region contains multi-
ple promoter-like elements including 14 different
transcription factor binding sites. Each cassette
also contains a poly-A tail. All three were packaged
into AAV serotype 9 (AAV9) capsids due to this
Figure 1. AAV-TAZ vector designs and RNA transcription levels. (A) Depiction of the three different TAZ-myc + Poly A tail constructs, each containing a
different promoter and flanked by AAV-ITRs mutated to form double-stranded vectors (indicated by D). No significant difference between promoters was
observed in vector genomes (vg) per diploid cell across tissues from mice treated as adults (3 months of age) (B) or as neonates (1–2 days of age) (C). Human
TAZ RNA transcript expression levels were evaluated in tissues from mice injected as adults (D) and neonates (E). (F) Gel showing representative bands for
each tissue generated with TAZ (top) and 18S (bottom) gene expression probes for each sample. Data are represented as mean – SEM (n = 6). Significant
differences between promoters were determined using the Kruskal–Wallis test (*p £ 0.05, **p £ 0.01, ***p £ 0.001). ad, adult; AAV, adeno-associated virus; Br,
brain; CMV, cytomegalovirus; Des, desmin; Ga, gastrocnemius; Ht, heart; ITR, inverted terminal repeat; Ki, kidney; Li, liver; Lu, lung; neo, neonatal; So, Soleus; S,
spleen; TazKD, tafazzin short hairpin RNA knockdown; WT, wild type.
GENE THERAPY CORRECTION OF BARTH SYNDROME 143
D
ow
nl
oa
de
d 
by
 W
as
hi
ng
to
n 
U
ni
v 
fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
5/
06
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
serotype’s high natural affinity for cardiac tissue
following intravenous administration.19
TazKD mice were intravenously administered
1 · 1013 vector genomes/kilogram of dsAAV9-CMV-
TAZ (CMV-TAZ), dsAAV9-Des-TAZ (Des-TAZ), or
dsAAV9-Taz-TAZ (Taz-TAZ) as neonates (1–2 days
of age; temporal vein) or adults (3 months of age;
jugular vein). Following live functional assessments
at 5 months, WT, untreated TazKD, and all six
treated TazKD cohorts were euthanized for various
tissue analyses. Vector genomes per diploid cell
were determined for all tissues collected in this
study (Fig. 1B and C). As expected, no differences in
vector genomes were observed between promoters
within the same tissue and injection age. These re-
sults confirm that the vector titers used were valid,
the mice were administered uniform vector doses,
and that any subsequent differences observed be-
tween mouse cohorts are a result of promoter effects.
Gene expression assays demonstrated that while
all three vectors successfully transcribed TAZ, the
different promoter sequences yielded varying TAZ
transcript levels and tissue expression biodistribu-
tions that were slightly altered depending upon
injection age. In the hearts of TazKD mice treated
as adults, the Des-TAZ vector resulted in signifi-
cantly higher TAZ gene expression levels than ei-
ther CMV-TAZ or Taz-TAZ and the CMV-TAZ
vector resulted in significantly higher TAZ gene
expression levels than Taz-TAZ (Fig. 1D). No sig-
nificant differences were observed between the
three promoters in soleus, gastrocnemius, liver,
brain, lung, kidney, or spleen from mice injected as
adults. In the hearts of TazKD mice treated as ne-
onates, both the Des-TAZ and Taz-TAZ vectors re-
sulted in significantly higher TAZ gene expression
levels than CMV-TAZ. The Des promoter also
yielded significantly higher TAZ transcript levels in
the soleus and significantly lower levels in liver as
compared to both the CMV-TAZ and Taz-TAZ
(Fig. 1E). There were no significant differences ob-
served between expression levels from the different
promoters in gastrocnemius, brain, lung, kidney, or
spleen from mice treated as neonates. cDNA prod-
ucts from the gene expression assays were resolved
on agarose gels and further confirmed these ex-
pression profile results (Fig. 1F).
Tafazzin protein expression was compared be-
tween the three promoters at both injection ages
using Western blotting (WB) and IF microscopy on
heart samples from each cohort. WB analysis with
an a-tafazzin antibody shows bands at the correct
size from whole heart lysate samples with the most
intense bands coming from the Des-TAZ vector in
mice injected as adults and lighter but prevalent
bands from all cohorts injected as neonates
(Fig. 2A). WB analysis on whole heart lysate sam-
ples with an a-Myc antibody shows a band at the
correct size with an intensity profile similar to
a-tafazzin in samples treated as adults with Des-
TAZ and more faintly in samples treated with each
promoter as neonates. WB analysis with an a-Myc
antibody on myc pulldown samples resulted in a
band only from the Des-TAZ vector in mice injected
as adults. Densitometry analyses of tafazzin/
GAPDH protein band intensity ratio means from
three separate whole heart lysate blots showed sig-
nificantly higher levels of tafazzin protein present in
hearts from Des-TAZ animals treated as adults as
compared to CMV and Taz (Fig. 2B). IF microscopy
was performed using (1) an antibody against the
mitochondrially encoded cytochrome C oxidase II
(MTCO2) protein to identify mitochondria (green)
and (2) an a-Myc antibody (red) to detect protein
expression from the delivered transgene (Fig. 2C–J).
Myc expression was absent in both WT and TazKD
controls (Fig. 2C and D) and detected by IF to some
degree in all treated cohorts where it mimicked RNA
transcript profiles and overlaid well with MTCO2
(Fig. 2E–J).
TAZ gene therapy improves whole
body activity in TazKD mice
To simulate previous exercise-induced fatigue
studies performed in human BTHS patients,
mouse activities were evaluated prior to and fol-
lowing exercise using an ActiTrack system. WT,
untreated TazKD, and all treated TazKD mice co-
horts were evaluated in their average resting times
(no movement), slow movement time, fast move-
ment time (‡5 cm/s), total distance travelled, and
number of vertical rearings prior to and immedi-
ately following 15 min of treadmill incline exercise.
Preexercise resting time was significantly reduced in
all treatment groups except Taz-TAZ mice treated as
adults and there were no differences observed be-
tween promoters (Fig. 3A). Postexercise resting time
was significantly reduced in all treatment groups
except for Taz-TAZ mice treated as neonates with
both the CMV-TAZ and Des-TAZ mice treated as
neonates displaying significantly improved times as
compared to Taz-TAZ mice (Fig. 3B). The average
slow movement times preexercise were signifi-
cantly improved in all treatment cohorts as com-
pared to untreated controls except for CMV-TAZ
mice treated as neonates with a significant differ-
ence between the CMV-TAZ and Taz-TAZ vectors
in mice treated as adults (Fig. 3C). The average
slow movement times postexercise were signifi-
cantly improved in all treatment cohorts with mice
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treated with the Des-TAZ vector as neonates
showing significantly more improvement as com-
pared to the other two promoters (Fig. 3D).
Average fast movement time was significantly
increased in all treatment groups as compared to
untreated TazKD controls both preexercise (Fig. 3E)
and postexercise (Fig. 3F). CMV-TAZ mice showed
significant improvement over Taz-TAZ mice treated
as adults preexercise and Des-TAZ mice showed
significant improvement in postexercise fast move-
ment time over both other promoters in mice treated
as neonates with CMV-TAZ also showing signifi-
cant improvement over Taz-TAZ mice treated as
neonates. Preexercise total distance travelled was
significantly increased in all treatment groups
and no significant differences were observed be-
tween promoters (Fig. 3G). Postexercise total
distance travelled was also significantly increased
in all treatment groups with Des-TAZ mice trea-
ted as neonates displaying significant improve-
ment over both of the other promoters (Fig. 3H).
The preexercise average number of rearings
(number of times mice reach vertically and cross a
horizontal plane) was significantly increased in
all treatment groups over untreated TazKD mice
with Des-TAZ mice treated as neonates showing
significant improvement over both other promot-
ers (Supplementary Fig. S1A). The postexercise
average number of rearings was significantly in-
creased in all treatment groups except for Taz-
TAZ mice treated as adults and mice treated with
Des-TAZ as neonates showed significant improve-
ment over those treated with Taz-TAZ (Supple-
mentary Fig. S1B).
Figure 2. Tafazzin protein expression comparisons between AAV-TAZ vectors following delivery to adult or neonatal TazKD mice. (A) Representative
Western blot analyses using (1) a-Myc antibody, (2) a-tafazzin antibody, (3) GAPDH control antibody on whole heart lysates, or (4) a-Myc antibody on Myc-bead
purified (pulldown) heart lysate samples. (B) Graph depicting tafazzin/GAPDH Western blot density ratios for whole heart lysate samples. Data are represented
as Mean – SEM (n = 3 biological replicates). Significant differences between promoters for each treatment age are indicated by lines above bars and
significant improvement between each individual sample and untreated TazKD controls is indicated at the bottom of bars (*p £ 0.05, **p £ 0.01, ***p £ 0.001).
(C–J) Immunofluorescence analyses of the MTCO2 mitochondrial protein (left panel for each) and the Myc tag (middle panel for each) and an overlay of the
two including DAPI in blue (right panel for each) shows no Myc expression in WT (C) or TazKD (D) mouse heart sections and varying levels of expression in
hearts representing mice from all treatment cohorts: CMV-TAZad (E); CMV-TAZneo (F); Des-TAZad (G); Des-TAZneo (H); Taz-TAZad (I); and Taz-TAZneo (J).
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Activity maps generated for each mouse pre and
post exercise further demonstrate the impact of
tafazzin deficiency on overall movement. WT and
treated TazKD mice were able to more quickly as-
sess their environment and better explore territory
within the arena (Supplementary Fig. S2A–D and
F–H). As untreated TazKD mice spent more time
resting or moving slowly, it took longer for these
mice to become comfortable with their surround-
ings and explore the center of the arena and thus,
less of the arena area was explored (Supplemen-
tary Fig. S2E). Of note, among treatment groups,
mice injected with the Taz-TAZ vector (although
significantly improved over untreated TazKD con-
trols) show the least improvement in movement type
and territory coverage (Supplementary Fig. S2D and
H). Taken together, ActiTrack data demonstrate
significant improvements in body function and ex-
ercise tolerance in AAV treated TazKD mice as
compared to untreated TazKD controls.
TAZ gene therapy improves cardiac
function in TazKD mice
Echocardiography (echo) analyses were per-
formed to compare cardiac function between all
treatment cohorts at 5 months of age. All treatment
groups showed significant improvements in frac-
tional shortening with Taz-TAZ mice showing sig-
nificant improvement over CMV-TAZ and Des-TAZ
vectors in mice treated as adults (Fig. 4A). All treat-
ment groups showed significant improvements in
ejection fraction with Taz-TAZ mice showing sig-
nificant improvement over CMV-TAZ and Des-TAZ
vectors in mice treated as adults (Fig. 4B). A table
of the echo data used to generate these graphs is
provided (Supplementary Table S3). Heart weight/
body weight ratios were significantly improved in
all treatment cohorts as compared to untreated
TazKD controls except CMV-TAZ and Taz-TAZ
treated as neonates with no differences observed
between promoters (Fig. 4C).
Muscle force mechanics testing
reveals differences in promoters’
abilities to improve soleus muscle
strength and fatigue
Ex vivo force mechanics evaluations were per-
formed on excised soleus muscles from mice in all
groups at five months of age. TazKD mice treated
with either CMV-TAZ or Des-TAZ as neonates or
adults all displayed a significant decrease in fati-
gability as compared to untreated TazKD controls
Figure 4. Cardiac function and heart weight characterizations. A significant decrease in FS% (A) and EF% (B) is observed in TazKD (dashed line) as
compared to WT (dotted line) mice (p £ 0.001). These measurements were both increased in all treated cohorts. (C) TazKD mice also display a significantly
increased heart weight/body weight ratio as compared to WT controls ( p £ 0.001) that is decreased in all treated cohorts except CMV-TAZ and Taz-TAZ mice
treated as neonates. Data are represented as mean – SEM (n = 8). Significant differences between promoters for each treatment age are indicated by lines
above bars and significant improvement between each individual sample and untreated TazKD controls is indicated by * at the bottom of bars (*p £ 0.05,
**p £ 0.01, ***p £ 0.001). FS, fractional shortening; EF, ejection fraction.
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(Fig. 5A–C). Mice treated as adults with CMV-TAZ
or Des-TAZ both showed significant improvement
in fatigability (final value of maximum force pre-
sented as a percentage of initial force) over mice
treated with Taz-TAZ (Fig. 5C). Mice treated with
Des-TAZ as neonates showed significant improve-
ment in fatigability over both the other promoters.
All treatment groups displayed significantly high-
er tetanic contractile force as compared to un-
treated TazKD controls (Fig. 5D–F). Mice treated
as neonates with Des-TAZ showed significant im-
provement in peak isometric tetanic force over mice
treated with CMV-TAZ (Fig. 5F).
TAZ gene therapy improves
mitochondrial structural defects
Electron micrographs (EM) of hearts from un-
treated TazKD, WT controls, and mice in all
treatment cohorts were examined to evaluate mi-
tochondrial structure. Dramatic differences in mi-
tochondrial size, numbers, and cristae organization
were observed in EM images from healthy WT and
untreated TazKD controls (Fig. 6A and E). All EM
images from mice treated as adults show mito-
chondria that appear improved with regards to
organization along sarcomeres, general size, and
mitochondrial numbers and mice treated with ei-
ther CMV-TAZ or Des-TAZ display improved cris-
tae organization (Fig. 6B–D). All EM images from
mice treated as neonates show mitochondria that
appear improved with regards to decreased clus-
tering between sarcomeres, general size, and cris-
tae organization (Fig. 6F–G).
All treatment cohorts displayed significant im-
provements in mitochondrial area (increased rela-
tive to untreated TazKD controls) with mice
treated as adults with Des-TAZ and Taz-TAZ dis-
playing significant improvements over those trea-
ted with CMV-TAZ, and Taz-TAZ mice treated as
neonates showing significant improvements over
both of the other promoters (Fig. 6I). All cohorts
except for those treated with Des-TAZ as neonates
showed significant improvement in number of mi-
tochondria per field (decreased) as compared to
untreated TazKD controls with CMV-TAZ and Taz-
TAZ displaying significant improvement over Des-
TAZ mice treated as neonates (Fig. 6J). All cohorts
showed significant improvement in mitochondrial
Figure 5. Ex vivo soleus muscle fatigue and strength force mechanics data. (A, B) Increased fatigability is observed in TazKD mice (dashed line) as
compared with WT controls (dotted line) based upon comparisons of maximum tetanic force drop profiles of soleus muscles ( p £ 0.001). (C) Fatigability is
significantly improved in all treatment cohorts except for those treated with the Taz-TAZ vector as either adults or neonates with differences between
promoters indicated. (D, E) Soleus muscle strength based upon force frequency measurements is also significantly reduced in TazKD mice compared with WT
controls ( p £ 0.01). (F) Soleus muscle strength based upon peak isometric tetanic force is increased in all treatment cohorts with differences between
promoters indicated. Data are represented as mean – SEM (n = 6). Significant differences between promoters for each treatment age are indicated by lines
above bars and significant improvement between each individual sample and untreated TazKD controls is indicated at the bottom of bars (*p £ 0.05, **p £ 0.01,
***p £ 0.001).
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width (increased) as compared to untreated TazKD
controls with Taz-TAZ displaying significant im-
provement over CMV-TAZ and Des-TAZ display-
ing significant improvement over both other
promoters in mice treated as adults (Fig. 6K). Mice
treated with Taz-TAZ as neonates displayed a
significant improvement in mitochondrial width as
compared with both other promoters. In general,
these EM images suggest that improved inner
mitochondrial membrane organization, mitochon-
drial localization along sarcomeres, and a reduc-
tion in mitochondrial fragmentation is occurring in
the hearts of treated mice.
TAZ gene therapy improves cardiac
mitochondrial respiration
Oxygen consumption measurements were per-
formed on freshly isolated, respiration competent,
cardiac mitochondria from mice at 5 months of age
in all groups to examine differences in respiration
states using an Oxytherm Clark electrode appa-
ratus. Cardiac mitochondria from TazKD mice
displayed significantly reduced levels of state 3
(mitochondria + glutamate/malate + ADP) O2 con-
sumption rates as compared with cardiac mito-
chondria isolated from healthy WT control mice
(Fig. 7A). Significant improvements were observed
in state 3 O2 consumption rates from mice in all
TazKD treatment groups as compared to untreated
TazKD controls with no differences observed be-
tween promoters. Cardiac mitochondria from
TazKD mice also displayed significantly reduced
levels of state 4o (ADP is depleted, oligomycin
addition–ATP synthase inhibitor to prevent any
contribution from ATP recycling in the ETC) O2
consumption rates as compared with those iso-
Figure 6. Mitochondrial structure evaluations. (A–H) Representative EM images of cardiac mitochondria from WT, TazKD, and all AAV treatment cohorts. Fifteen
images from each of four samples were evaluated per group. (I–K) Quantitative evaluations of images (A–H) revealed significant differences between TazKD
(dashed line) and WT (dotted line) mitochondrial area, number, and width (***p £ 0.001). (I) Improved mitochondrial area was observed in all treatment cohorts. (J)
Improved number of mitochondria per field was observed in every cohort except for Des-TAZ mice treated as neonates. (K) Improved mitochondrial width was
observed in every cohort. Data are represented as mean – SEM. Significant differences between promoters for each treatment age are indicated by lines above bars
and significant improvement between each individual sample and untreated TazKD controls is indicated at the bottom of bars (*p £ 0.05, **p £ 0.01, ***p £ 0.001).
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lated from healthy WT control mice (Fig. 7B).
Significant improvements were found in state 4o
O2 consumption rates from mice in all treatment
groups as compared to untreated TazKD controls
with no differences observed between promoters.
Finally, cardiac mitochondria from TazKD mice
displayed significantly reduced levels of state 4u
(FCCP added to uncouple electron transport and
phosphorylation) O2 consumption rates as com-
pared to those isolated from healthy WT control
mice (Fig. 7C). Significant improvements were
found in all treatment groups with mice treated as
adults with the Des-TAZ vector showing signifi-
cant improvement over mice treated with CMV-
TAZ. These respiration state data demonstrate an
increased ability to consume oxygen in treated
mitochondria which suggests more efficient ETC
energy generation.
Mitochondrial ETC activities
Assays were performed to evaluate the activity
levels of mitochondrial electron transport chain CI,
CII, and CIII enzymes from lysates of isolated mi-
tochondria. A significant decrease in CI, CII, and
CIII activity levels was observed in TazKD mice as
compared to WT controls. CI activity levels were
significantly improved in all treatment cohorts as
compared to untreated TazKD controls and no dif-
ferences were observed between promoters at either
treatment age (Fig. 7D). CII levels were significantly
improved in Des-TAZ mice treated as neonates as
compared to untreated TazKD controls and CII ac-
tivity in this cohort was significantly improved over
both other promoters from the same injection age
(Fig. 7E). CIII levels were not significantly improved
in treated mice (Fig. 7F). These data provide further
support that ETC energy generation is improved to
some degree in all treatment cohorts.
Tabulated scores from all measurements
We developed a scoring system to determine
which of the three promoters compared in this
study (CMV, Des, or Taz) provided the highest
number of desirable outcomes. Degree of signifi-
cant improvement over untreated TazKD con-
trols is indicated by the intensity of yellow shading
(darker shading represents more significantly im-
proved). Each box also indicates whether that
vector and injection timepoint provide a result that
is not significantly (ns) improved or is significantly
Figure 7. Cardiac mitochondrial function analyses: O2 consumption and electron transport chain complex activities. A significant decrease in O2
consumption rates state 3 (A), state 4o [oligomycin added] (B), and state 4u [uncoupled] (C) was observed in mitochondria isolated from the hearts of
TazKD (dashed line) as compared to WT (dotted line) mice ( p £ 0.001). State 3 and state 4o activities were significantly increased in mitochondria isolated
from all treatment cohorts and state 4u activity was significantly improved in the mice treated as adults. Cardiac mitochondrial complex I (CI), complex II
(CII), and complex III (CIII) activities were evaluated and compared with WT (dotted line set at 100% activity). A significant decrease in activities was
observed in TazKD (dashed line) compared with WT mice: CI ( p £ 0.001), CII ( p £ 0.05), CIII ( p £ 0.05). (D) All treated cohorts showed significant
improvement in CI activity. (E) Only Des-TAZ mice treated as neonates displayed improvement in CII activity. (F) No treatment cohort displayed significant
improvement in CIII activity levels. Data are represented as mean – SEM (n = 5). Significant differences between promoters for each treatment age are
indicated by lines above bars and significant improvement between each individual sample and untreated TazKD controls is indicated at the bottom of bars
(*p £ 0.05, **p £ 0.01, ***p £ 0.001).
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improved over one (+) or both (++) of the other two
promoters. The tabulated scores (Table 1, bottom)
show that Des-TAZ is the most optimal promoter
for amelioration of overall BTHS pathophysiology,
followed by CMV-TAZ, and finally, by Taz-TAZ
regardless of gene therapy administration age.
DISCUSSION
As previous studies have demonstrated signifi-
cantly impaired cardiac and skeletal muscle bioen-
ergetics and exercise intolerance in BTHS-affected
human patients, we sought to develop a gene ther-
apy vector that would successfully treat both cardiac
and skeletal muscle dysfunctions in BTHS.11,13 This
study evaluated the in vivo performance of three
different promoters within TAZ gene delivery vec-
tors (CMV, Des, and Taz). We were particularly in-
terested identifying a promoter able to provide
robust expression to cardiac and skeletal muscle
with simultaneous low expression in the liver and
other organs not impacted by BTHS as this would
improve the safety and effectiveness of noninvasive
intravenous gene therapy administration into hu-
man BTHS patients.
As the use of an AAV serotype with a high nat-
ural tropism for both cardiac and skeletal muscle
is particularly advantageous for disorders such as
BTHS, our study tested each of the three promoters
packaged into AAV9 capsids. Due to a highly suc-
cessful example of the use of AAV9 for spinal
muscular atrophy 1 gene therapy, there is now a
president for the safety and use of AAV9 as a clin-
ical gene delivery vehicle.39 Our experiments were
performed using a well-established doxycycline-
inducible shRNA knockdown mouse model of
Table 1. Barth syndrome gene therapy promoter comparison summary
Measurement (most desirable outcome) CMVAd DesAd TazAd CMVNeo DesNeo TazNeo
TAZ transcription (high in heart) + ++ ns ns + +
TAZ transcription (high in skeletal muscle—soleus) ns ns ns ns ++ ns
TAZ transcription (low in nonmuscle tissues—liver) ns ns ns ns ++ ns
TAZ translation (increased protein - WB) ns ++ ns ns ns ns
Pre-exercise activity - Resting time (decreased) ns ns ns ns ns ns
Pre–exercise activity – slow movement (decreased) + ns ns ns ns ns
Pre–exercise activity – fast movement (increased) + ns ns ns ns ns
Pre–exercise activity – average distance (increased) ns ns ns ns ns ns
Pre–exercise activity – rearing (increased) ns ns ns ns ++ ns
Post–exercise activity – resting time (decreased) ns ns ns + + ns
Post–exercise activity – slow movement (decreased) ns ns ns ns ++ ns
Post–exercise activity – fast movement (increased) ns ns ns + ++ ns
Post–exercise activity – average distance (increased) ns ns ns ns ++ ns
Post–exercise activity – rearing (increased) ns ns ns ns + ns
Echocardiography – ejection fraction (increased) ns ns ++ ns ns ns
Echocardiography – fractional shortening (increased) ns ns ++ ns ns ns
Heart weight/body weight ratios (decreased) ns ns ns ns ns ns
Force mechanics (decreased fatigability) ns + ns ns + ns
Force mechanics (increased strength) ns ns ns ns + ns
Mitochondrial number (decreased) ns ns ns + ns +
Mitochondrial area (increased) ns + + ns ns ++
Mitochondrial width (increased) ns ++ + ns ns ++
Mitochondrial oxygen consumption – state 3 (increased) ns ns ns ns ns ns
Mitochondrial oxygen consumption — state 4o (increased) ns ns ns ns ns ns
Mitochondrial oxygen consumption — state 4u (increased) ns + ns ns ns ns
Mitochondrial complex I activity (increased) ns ns ns ns ns ns
Mitochondrial complex II activity (increased) ns ns ns ns ++ ns
Mitochondrial complex III activity (increased) ns ns ns ns ns ns
Significant improvement over one other promoter within the same injection age (+). Total score: 3 3 2 3 5 2
Significant improvement over both other promoters within the same injection age (++). Total score: 0 3 2 0 7 2
Measurements significantly improved as compared to untreated TazKD ( p £ 0.05). Total score: 6 5 5 5 2 7
Measurements significantly improved as compared to untreated TazKD ( p £ 0.01) Total score: 8 7 7 6 10 4
Measurements significantly improved as compared to untreated TazKD ( p £ 0.001) Total score: 10 12 8 10 13 9
Sum of all improved outcomes: 27 30 24 24 37 24
All measurements conducted in this study are listed in the column on the left, with the most desirable outcome indicated in parentheses. The six columns to
the right correspond to each promoter and age of treatment described in the study. The yellow shading indicates a direct comparison of how significantly
improved that measurement is over untreated TazKD controls (dark yellow, p £ 0.001; medium yellow, p £ 0.01; and light yellow, p £ 0.05). The significance of
outcomes as compared with the other promoters is indicated for every measurement under each cohort with either ns (no significant improvement with this
promoter over either of the other promoters), + (significant improvement with this promoter over one of the other promoters), or ++ (significant improvement
with this promoter over both other promoters) at that same age of administration. The bottom of the table provides a summary breakdown score quantifying
significance indicators for each treatment group, with total sums presented in the bottom row. WB, Western blotting.
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BTHS. All mice were maintained on a dox diet
throughout the study to control for any possible
effects from doxycycline alone. We did not detect
any effect of dox on AAV distribution as the overall
vector distributions observed in our study were
comparable to those profiles observed in other
AAV9 characterization studies performed in mice
without doxycycline.18,19,23 Some mice were trea-
ted as neonates (1–2 days) while others were trea-
ted as adults (3 months) to determine whether a
different promoter would be more optimal for a
particular age of treatment and confirm that a gene
delivery approach is relevant for both infants and
young men with BTHS.
While all three promoters provided substantial
TAZ expression, the Des promoter provided the
most optimal TAZ transcription level profiles with
significantly higher expression in heart (both treat-
ment ages) and skeletal muscle (neonatal adminis-
tration), and significantly lower expression in liver
(neonatal administration) as compared with the
other two promoters. As expected, the CMV pro-
moter demonstrated strong transcript expression
levels across a variety of tissues and generally good
functional improvement. However, it resulted in
lower cardiac and higher liver expression than the
Des promoter. By comparison, the Taz promoter
displayed relatively low expression levels in the
heart when delivered to adult mice, relatively high
expression levels in the liver when delivered to
neonates and resulted in the least overall func-
tional improvement. Although BTHS primarily
affects heart and skeletal muscle, tafazzin is nor-
mally expressed at low levels in many different
tissues throughout the body; thus, the wide distri-
bution of transcript expression generated from this
native sequence is not entirely surprising.40 As-
sessments of protein expression levels in the heart
revealed improvement in most treated cohorts as
compared to untreated controls. As anticipated
based upon RNA transcript data, Des-TAZ ad-
ministration to adult mice resulted in the highest
levels based on both myc-tag pulldown and direct
WB on whole-heart lysates.
Cardiac function, muscle strength, and exercise
tolerance are all key features of BTHS that con-
tribute to morbidity, mortality, and overall quality
of life for these patients.10–13,41 Therefore, it was
important to ensure that our gene therapy strat-
egy addressed the complete pathophysiology of
BTHS. Significant improvement was observed in
in vivo cardiac function and heart weight/body
weight ratios in all treatment cohorts as com-
pared to untreated controls. O2 consumption in
isolated respiration competent cardiac mitochon-
dria and mitochondrial area were also signi-
ficantly improved in all treatment cohorts as
compared to untreated TazKD controls sugges-
ting that achieving a modest increase in TAZ ex-
pression can have a dramatic impact on heart
function in BTHS.
In vivo mouse activity and fatigability assess-
ments (ActiTrack) demonstrated the ability of
our gene therapy strategy to successfully improve
whole body function. While differences between
individual promoters were observed in several of
these measurements, both the CMV-TAZ and Des-
TAZ vectors demonstrated significant improvement
over untreated controls in all ActiTrack assess-
ments. Administration of the Des-TAZ vector to
neonates resulted in statistically significant im-
provement (decreased fatigue) as compared with
both other promoters in postexercise evaluations of
slow movement time, fast movement time, and
average distance travelled. Indeed, several treat-
ment cohorts showed increased activity as com-
pared with WT mice, which suggests that increased
TAZ expression in muscle can increase mitochon-
drial energy production and dramatically improve
function. Future overexpression studies to evalu-
ate the impact of tafazzin overexpression in WT
mice would confirm this and may mimic the results
of previous mouse muscle exercise evaluations
where metabolic adaptations improved mitochon-
drial function.42,43 Results from our ex vivo force
mechanics assessments provide further support
that TAZ gene delivery has the ability to improve
strength and fatigability in BTHS. Together, our
data suggest that increased TAZ expression in
skeletal muscle can provide a key functional en-
hancement that will greatly improve quality of life
for BTHS patients. As previous clinical studies
demonstrated clear evidence for increased muscle
fatigue in human BTHS patients due to inefficient
O2 utilization, an improvement in this parameter
represents an important outcome measure for
these patients.11,13
If considered alone, any one of these vectors
would appear beneficial as a therapy for BTHS.
The direct comparison of three different thera-
peutic vectors presented in this study provides a
basis for comparison that enables selection of the
vector that is truly most optimal for translation
into the clinic. In order to more easily visualize and
consider how these promoters performed against
one another, each vector’s performance for every
measurement included in the study was scored and
tabulated. This approach identified the Des-TAZ
vector as being the most prominently effective in
BTHS mice treated as either adults or neonates
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due to its overall ability to provide improvement to
organelle, organ, and whole body function.
Future investigations will include development
and testing of a Des-TAZ vector that has been co-
don optimized for transcription in humans as well
as dose escalation studies in mice to more precisely
estimate the optimal amount of vector required for
a minimum effective dose and toxicology studies to
ensure vector safety. In sum, we present the first
demonstration of a potential definitive treatment
that significantly improves heart and skeletal
muscle function in BTHS whether delivered to very
young or fully grown mice. Importantly, no neg-
ative effects were observed in any of the mice ex-
posed to this therapeutic strategy. As a multitude
of AAV-mediated gene delivery strategies are
currently being evaluated for clinical efficacy in
humans to treat a range of genetically inherited
disorders (spinal muscular atrophy, hemophilia),
a strong precedent exists for our strategy to be
successfully implemented as a valid therapy.39,44
Thus, our study provides substantial support for
the translation of dsAAV9-Des-TAZ gene therapy
for BTHS into the clinical realm.
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